| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_273a788f0ad68a4f04a387bce6d34ce5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7d9e1c48e4e52eca5bf3b2c64dffa5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8c40ed97d54dc84fa1f1de6dbc1a739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14d79894562bf13548c33e0ff8923ebb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0016 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-53 |
| filingDate |
1998-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7229c9478f30ac4e93b480a28dd8e81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2f60367d404da51109e4b8d77870d52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10559fa9f34ff12ed9f8c7f00565f33b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1042a71061a17e4ec1aca372c4bc4b34 |
| publicationDate |
1998-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9832862-A2 |
| titleOfInvention |
L-alanine dehydrogenase of mycobacterium marinum |
| abstract |
Tuberculosis is an infectious disease which kills more than 3 million people every year. Although both a vaccine and various methods of diagnosis and treatment are available the efficacy of these measures is in urgent need of improvement, given that the number of new cases is again on the rise. Research focuses, among other things, on the characterization of antigens secreted in the early stages of the infection as they constitute the first point of contact of the immune system with the pathogen. The 40 KD-antigen discussed in this article is present $I(in vivo) as a hexamer and, despite its high molecular weight and lack of a signal sequence, is present extracellularly after only a few days of growth. Functionally it is an L-alanine dehydrogenase and reacts with the monoclonal antibody HBT-10 directed against this protein. HBT-10 was the first known antibody specific to a protein of M.tuberculosis which did not cross-react with the vaccine strain M.bovis BCG. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03089462-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6617116-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03089462-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2403477-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2403477-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9836089-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9836089-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6849414-B2 |
| priorityDate |
1997-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |